Raj K. Puri bought $9,743 of IOVA
Chief Regulatory Officer at IOVANCE BIOTHERAPEUTICS, INC.. 5,600 shares at an average of $1.74, traded May 23, 2025, filed May 27, 2025.
Score components
- +15RoleOfficer
- 0Trade size$10k at market
- 0Relative to holdingsHoldings up 2.8%
- +18Price context7% above the 52-week low; 86% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-052968, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 23, 2025 | POpen-market purchase Common Stock | +5,600 | $1.74 | $9,743 | 206,852 | May 27, 2025 |
Related signals
Other insiders at IOVANCE BIOTHERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | IOVANCE BIOTHERAPEUTICS, INC. | Daniel Gordon Kirby Chief Commercial Officer | $55k 30,000 shares | - | |
| 60Notable | IOVANCE BIOTHERAPEUTICS, INC. | Frederick G Vogt Interim CEO & General Counsel | $42k 25,000 shares | +7% | |
| 38Weak | IOVAsell IOVANCE BIOTHERAPEUTICS, INC. | Ryan D Maynard director | $503k 50,000 shares | -87% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.